Missed Periods: Drugs That Cause or Treat It

What Amenorrhea Actually Means

Amenorrhea is the medical term for absent menstrual periods. Clinicians split it into two categories: primary amenorrhea (no period by age 15 with otherwise normal development) and secondary amenorrhea (periods that stop for three or more consecutive months in someone who previously had regular cycles). This article focuses on secondary amenorrhea, because drug-induced and drug-treated cases fall almost entirely into that category.

The Distinction Matters Clinically

Primary amenorrhea usually signals a developmental or genetic condition (Turner syndrome, Müllerian agenesis). Secondary amenorrhea, by contrast, often has a reversible pharmacological or hormonal trigger. The American College of Obstetricians and Gynecologists (ACOG) Practice Bulletin No. 108 recommends evaluating any patient with three missed cycles or more, even if they suspect a medication is the cause [1].

Prevalence and Scope

Population-based data suggest secondary amenorrhea affects 3 to 4% of reproductive-age women at any given time, excluding pregnancy and lactation [2]. That figure climbs sharply in specific clinical populations. Among women prescribed high-dose antipsychotics, amenorrhea rates reach 50 to 90% depending on the agent [3]. Among competitive athletes and women with eating disorders, prevalence ranges from 20 to 44% [4].

Drugs That Cause Missed Periods

The list of medications that can suppress menstruation is longer than most patients expect. These agents work through several distinct mechanisms: hyperprolactinemia, direct hypothalamic suppression, ovarian suppression, and endometrial atrophy.

Antipsychotics and Hyperprolactinemia

Conventional (first-generation) antipsychotics like haloperidol block dopamine D2 receptors in the tuberoinfundibular pathway, removing the tonic inhibition of prolactin release. Elevated prolactin suppresses gonadotropin-releasing hormone (GnRH) pulsatility, which in turn shuts down the menstrual cycle. A 2004 study published in the Journal of Clinical Psychopharmacology found that 78% of women on risperidone developed hyperprolactinemia, and 48% reported amenorrhea or oligomenorrhea [3].

Atypical antipsychotics vary widely. Risperidone and paliperidone are the worst offenders, while aripiprazole (a partial dopamine agonist) is the least likely to raise prolactin. Quetiapine and clozapine fall somewhere in between. A systematic review in Schizophrenia Research confirmed that switching from risperidone to aripiprazole restored normal prolactin and menses in most patients within 8 to 12 weeks [5].

Hormonal Contraceptives

Combined oral contraceptives, hormonal IUDs, and injectable progestins all suppress menstruation by design or as a side effect. Depot medroxyprogesterone acetate (Depo-Provera) causes amenorrhea in approximately 50% of users by 12 months and 68% by 24 months, according to FDA prescribing information [6]. Continuous-use combined pills and the levonorgestrel IUD (Mirena) also reduce or eliminate withdrawal bleeds. These are expected pharmacological effects, not adverse events.

GnRH Agonists and Antagonists

Leuprolide (Lupron), goserelin (Zoladex), and the newer oral GnRH antagonist elagolix (Orilissa) suppress the hypothalamic-pituitary-ovarian axis directly. They are prescribed specifically to induce a temporary, reversible menopause-like state for conditions including endometriosis, uterine fibroids, and precocious puberty. In the Phase III Elaris EM-I and EM-II trials, elagolix 200 mg twice daily produced amenorrhea in 46.4% of participants at 6 months [7]. Menses typically return within 4 to 8 weeks of discontinuation.

Chemotherapy Agents

Alkylating agents (cyclophosphamide, busulfan, chlorambucil) are directly gonadotoxic, damaging ovarian follicles in a dose- and age-dependent manner. A woman receiving cyclophosphamide at age 35 has roughly a 40% chance of permanent ovarian failure; at 25, the risk drops to about 15% [8]. Younger ovaries have a larger follicular reserve to absorb the damage. Unlike antipsychotic-induced amenorrhea, chemotherapy-related ovarian failure may be irreversible.

Other Drug Classes

Several additional medications cause missed periods through varied mechanisms:

• Metoclopramide and domperidone raise prolactin similarly to antipsychotics, though to a lesser degree.
• Opioids suppress GnRH pulsatility centrally. A 2010 study in The Journal of Clinical Endocrinology & Metabolism found that 29% of women on long-term opioid therapy developed amenorrhea or oligomenorrhea [9].
• High-dose corticosteroids (prednisone 20+ mg/day chronically) can suppress the hypothalamic-pituitary-gonadal axis.
• Certain antiepileptics, particularly valproate, are associated with menstrual irregularity and polycystic ovary morphology in up to 40 to 60% of female users, as reported in a Neurology study [10].

Diagnosing the Cause of Missed Periods

The diagnostic workup for amenorrhea follows a well-established algorithm. ACOG and the Endocrine Society both recommend a stepwise approach beginning with the simplest explanations and moving toward more complex testing only when initial results are inconclusive [1][11].

Step 1: Rule Out Pregnancy and Check Baseline Labs

A serum beta-hCG is mandatory. Even patients who report no sexual activity or who are on contraception require this test. Alongside hCG, the initial panel includes TSH (to rule out thyroid dysfunction), prolactin, and FSH.

Step 2: Interpret the Hormone Panel

• Elevated prolactin (above 25 ng/mL) points toward a prolactinoma, drug-induced hyperprolactinemia, or hypothyroidism (which itself raises prolactin via TRH stimulation). An MRI of the sella turcica is indicated for prolactin levels above 100 ng/mL.
• Elevated FSH (above 40 mIU/mL on two draws) suggests premature ovarian insufficiency or ovarian failure.
• Low or normal FSH with low estradiol points toward hypothalamic amenorrhea, often related to stress, low body weight, excessive exercise, or central suppression from medication.
• Normal labs across the board often indicate an outflow tract problem (Asherman syndrome) or polycystic ovary syndrome (PCOS), the latter being confirmed by additional criteria including androgen levels and pelvic ultrasound.

Step 3: The Progestin Challenge

The progestin withdrawal test helps determine whether a patient has adequate endogenous estrogen. Medroxyprogesterone acetate (Provera) 10 mg daily for 10 days is the standard protocol. Withdrawal bleeding within 2 to 7 days of completing the course confirms that estrogen levels are sufficient to prime the endometrium and that the outflow tract is patent. No withdrawal bleed suggests either very low estrogen (hypothalamic cause) or an anatomical obstruction [1].

Drugs Used to Treat Missed Periods

Treatment selection depends entirely on the underlying diagnosis. There is no single "fix" for amenorrhea; the goal is to address the root cause, restore ovulation if fertility is desired, and protect bone density if periods cannot be restored.

Medroxyprogesterone for Anovulatory Amenorrhea

For women with PCOS or chronic anovulation who have adequate estrogen levels, cyclic medroxyprogesterone acetate (MPA) 10 mg daily for 10 to 14 days each month induces a predictable withdrawal bleed and prevents endometrial hyperplasia. This does not restore ovulation but protects the uterine lining from unopposed estrogen stimulation, a known risk factor for endometrial cancer [12]. The approach is first-line when fertility is not immediately desired.

Combined Estrogen-Progestin Therapy

When estrogen levels are low (as in hypothalamic amenorrhea), estrogen replacement is needed to protect bone density and prevent genitourinary atrophy. Combined oral contraceptives or transdermal estradiol patches (typically 100 mcg/day) paired with cyclic progesterone (micronized progesterone 200 mg for 12 days per month) are standard options.

A 2019 meta-analysis in The Journal of Clinical Endocrinology & Metabolism showed that women with functional hypothalamic amenorrhea who received transdermal estradiol had a 2.8% annual gain in lumbar spine BMD versus a 1.5% annual loss in untreated controls [13].

Dopamine Agonists for Prolactinoma

Cabergoline and bromocriptine lower prolactin by activating dopamine D2 receptors. They are first-line therapy for prolactin-secreting pituitary adenomas, regardless of tumor size. Cabergoline is preferred: in a landmark New England Journal of Medicine study, cabergoline normalized prolactin in 83% of patients versus 59% for bromocriptine, with fewer gastrointestinal side effects [14]. Menses resume in over 90% of women whose prolactin normalizes. Starting dose is typically 0.25 mg twice weekly, titrated up based on prolactin response.

Clomiphene and Letrozole for Ovulation Induction

When the goal is pregnancy, clomiphene citrate 50 to 150 mg daily for 5 days (cycle days 3 to 7 or 5 to 9) is a standard first-line ovulation-induction agent for women with PCOS or anovulatory amenorrhea. Letrozole 2.5 to 7.5 mg daily for 5 days has increasingly replaced clomiphene as first-line in PCOS. The NEJM-published Pregnancy in PCOS II (PPCOS II) trial (N=750) showed live birth rates of 27.5% with letrozole versus 19.1% with clomiphene over 5 cycles [15].

Pulsatile GnRH for Hypothalamic Amenorrhea

For hypothalamic amenorrhea where fertility is desired and the patient has not responded to behavioral interventions (weight restoration, stress reduction), pulsatile GnRH delivered via a subcutaneous pump mimics the body's natural signaling. It restores ovulatory cycles in approximately 80 to 90% of cases, with cumulative pregnancy rates exceeding 80% over 6 cycles [16]. Availability is limited to specialized reproductive endocrinology centers.

Metformin as Adjunctive Therapy

Metformin 1,500 to 2,000 mg/day has a role in restoring menstrual cyclicity in PCOS patients, particularly those with insulin resistance and a BMI above 30. A Cochrane review found that metformin improved menstrual frequency compared to placebo (OR 1.72, 95% CI 1.14 to 2.61), though the effect on ovulation was modest and inferior to clomiphene as monotherapy [17].

When Drug-Induced Amenorrhea Requires Intervention

Not every case of drug-induced amenorrhea needs treatment. A woman on a levonorgestrel IUD who has no periods and no symptoms may need nothing beyond reassurance. The decision to intervene hinges on three questions.

Is Bone Density at Risk?

Hypoestrogenic amenorrhea (from GnRH agonists, hypothalamic suppression, or premature ovarian insufficiency) causes bone loss at rates comparable to postmenopausal osteoporosis. The American Association of Clinical Endocrinologists (AACE) recommends DEXA scanning for any reproductive-age woman with amenorrhea lasting 6 months or longer [18]. If Z-scores fall below -2.0, estrogen replacement should be started even if the patient is not seeking fertility.

Is Fertility Desired Now?

The urgency and choice of treatment shift substantially when a patient wants to conceive. Dopamine agonists, ovulation-induction agents, and pulsatile GnRH all serve this goal. For drug-induced amenorrhea, medication substitution (switching from risperidone to aripiprazole, for example) is often the simplest path.

Is the Endometrium Protected?

Chronic anovulation with adequate estrogen creates a state of unopposed estrogen exposure. Without periodic progesterone-driven shedding, the endometrial lining thickens abnormally. The Endocrine Society 2017 Clinical Practice Guideline recommends that women with PCOS-related amenorrhea receive cyclic progestins or combined hormonal contraceptives to induce at least 4 withdrawal bleeds per year to reduce endometrial cancer risk [11].

Specific Drug-to-Drug Switch Strategies

When a medication is causing amenorrhea and an alternative exists, switching is often preferable to adding a corrective therapy.

Antipsychotic Switches

Switching from risperidone to aripiprazole is the best-studied approach. Aripiprazole's partial dopamine agonism actually lowers prolactin. A Journal of Clinical Psychiatry study found that adding aripiprazole 10 to 15 mg to an existing risperidone regimen normalized prolactin in 68% of patients within 8 weeks, restoring menses in most [5]. Quetiapine and olanzapine are intermediate options when aripiprazole is not clinically appropriate for the psychiatric condition being treated.

Contraceptive Switches

If amenorrhea on Depo-Provera is distressing to the patient, switching to a combined oral contraceptive provides predictable withdrawal bleeds while maintaining pregnancy prevention. Alternatively, the copper IUD (Paragard) is a non-hormonal option that preserves natural menstrual patterns.

Opioid-Related Strategies

For opioid-induced hypogonadism causing amenorrhea, dose reduction or rotation to buprenorphine (which has less GnRH-suppressive effect) may restore cycles. If opioid therapy cannot be changed, transdermal estradiol with cyclic progesterone protects both bone and the endometrium [9].

Lifestyle Factors That Interact With Drug-Induced Amenorrhea

Medications rarely act in isolation. A woman taking valproate who also has a BMI of 32 and insulin resistance has multiple converging risk factors for amenorrhea. Addressing modifiable contributors alongside medication management improves outcomes.

Body Weight and Energy Availability

Energy availability below 30 kcal/kg of lean body mass/day suppresses the hypothalamic-pituitary-ovarian axis regardless of BMI. This threshold was established in the landmark Journal of Clinical Endocrinology & Metabolism study by Loucks and Thuma, which showed that LH pulsatility became disordered below this caloric threshold [4]. Athletes on medications that further suppress GnRH (opioids, high-dose corticosteroids) are at compounded risk.

Stress and Cortisol

"Functional hypothalamic amenorrhea is, at its core, a stress-adaptation response," wrote Dr. Catherine Gordon in her 2010 review in Annals of the New York Academy of Sciences [19]. Elevated cortisol from chronic psychological stress suppresses GnRH pulsatility through the same pathway as caloric deficit. Cognitive behavioral therapy (CBT) restored menstrual cycles in 87.5% of participants in a small randomized trial published in Fertility and Sterility (N=16), compared to 25% in the observation group [20].

Monitoring Timeline for Amenorrhea Treatment

Once treatment begins, expectations should be set clearly. Prolactin normalization with cabergoline typically occurs within 2 to 4 weeks, with menses returning 4 to 8 weeks after that. Hypothalamic amenorrhea treated with estrogen-progestin therapy produces a withdrawal bleed by the end of the first cycle. Clomiphene or letrozole ovulation induction should show a response (follicular development on ultrasound) within the first 1 to 2 treatment cycles.

For bone density monitoring, repeat DEXA is recommended 1 to 2 years after starting estrogen therapy, per AACE guidelines [18]. Prolactin levels should be rechecked 4 weeks after each dose adjustment of a dopamine agonist. Patients on cyclic MPA for endometrial protection need reassessment annually, including evaluation of ongoing amenorrhea cause and consideration of whether the underlying condition has resolved.